The Manufacturers Life Insurance Company Increases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

The Manufacturers Life Insurance Company increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 26.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 128,380 shares of the company's stock after buying an additional 26,519 shares during the period. The Manufacturers Life Insurance Company owned about 0.20% of Vera Therapeutics worth $5,429,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of VERA. Avoro Capital Advisors LLC boosted its stake in shares of Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after acquiring an additional 1,300,410 shares during the period. Lord Abbett & CO. LLC lifted its holdings in Vera Therapeutics by 170.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company's stock worth $48,788,000 after purchasing an additional 727,656 shares in the last quarter. Federated Hermes Inc. boosted its stake in Vera Therapeutics by 162.2% in the 4th quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock worth $45,926,000 after purchasing an additional 671,881 shares during the period. Voya Investment Management LLC raised its position in shares of Vera Therapeutics by 572.2% during the fourth quarter. Voya Investment Management LLC now owns 695,091 shares of the company's stock valued at $29,395,000 after buying an additional 591,682 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Vera Therapeutics by 11.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock worth $185,107,000 after buying an additional 437,940 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on VERA. HC Wainwright assumed coverage on shares of Vera Therapeutics in a research note on Monday, May 5th. They set a "buy" rating and a $75.00 target price for the company. Cantor Fitzgerald reduced their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday. Wolfe Research began coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target for the company. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group assumed coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $63.80.

Vera Therapeutics Trading Down 1.2 %

NASDAQ VERA traded down $0.26 on Friday, hitting $21.77. 1,262,456 shares of the stock were exchanged, compared to its average volume of 779,548. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $51.61. The firm has a market capitalization of $1.39 billion, a P/E ratio of -8.34 and a beta of 1.28. The stock has a fifty day moving average price of $24.22 and a two-hundred day moving average price of $34.72.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period in the prior year, the firm earned ($0.56) EPS. Research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.